Suppr超能文献

靶向HAT结构域的活性CBP/EP300降解剂的发现与表征

Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain.

作者信息

Cheng-Sánchez Iván, Gosselé Katherine A, Palaferri Leonardo, Kirillova Mariia S, Nevado Cristina

机构信息

Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.

Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.

出版信息

ACS Med Chem Lett. 2024 Jan 26;15(3):355-361. doi: 10.1021/acsmedchemlett.3c00490. eCollection 2024 Mar 14.

Abstract

Proteolysis Targeting Chimeras (PROTACs) are bifunctional molecules that simultaneously bind an E3 ligase and a protein of interest, inducing degradation of the latter via the ubiquitin-proteasome system. Here we present the development of degraders targeting CREB-binding protein (CBP) and E1A-associated protein (EP300)-two homologous multidomain enzymes crucial for enhancer-mediated transcription. Our PROTAC campaign focused on CPI-1612, a reported inhibitor of the histone acetyltransferase (HAT) domain of these two proteins. A novel asymmetric synthesis of this ligand was devised, while PROTAC-SAR was explored by measuring degradation, target engagement, and ternary complex formation . Our study demonstrates that engagement of Cereblon (CRBN) and a sufficiently long linker between the E3 and CBP/EP300 binders (≥21 atoms) are required for PROTAC-mediated degradation using CPI-1612 resulting in a new active PROTAC . Lessons learned from this campaign, particularly the importance of cell-based assays to understand the reasons underlying PROTAC performance, are likely applicable to other targets to assist the development of degraders.

摘要

蛋白酶靶向嵌合体(PROTACs)是双功能分子,可同时结合一种E3连接酶和一种目标蛋白,通过泛素-蛋白酶体系统诱导后者降解。在此,我们展示了针对CREB结合蛋白(CBP)和E1A相关蛋白(EP300)的降解剂的开发,这两种同源多结构域酶对增强子介导的转录至关重要。我们的PROTAC研究聚焦于CPI-1612,一种已报道的这两种蛋白的组蛋白乙酰转移酶(HAT)结构域抑制剂。设计了这种配体的新型不对称合成方法,同时通过测量降解、靶点结合和三元复合物形成来探索PROTAC的构效关系(SAR)。我们的研究表明,使用CPI-1612进行PROTAC介导的降解需要结合大脑神经酰胺酶(CRBN)以及E3与CBP/EP300结合剂之间有足够长的连接子(≥21个原子),从而产生一种新的活性PROTAC。从这项研究中吸取的经验教训,特别是基于细胞的分析对于理解PROTAC性能背后原因的重要性,可能适用于其他靶点,以协助降解剂的开发。

相似文献

1
Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain.
ACS Med Chem Lett. 2024 Jan 26;15(3):355-361. doi: 10.1021/acsmedchemlett.3c00490. eCollection 2024 Mar 14.
2
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity.
JACS Au. 2024 Aug 8;4(9):3466-3474. doi: 10.1021/jacsau.4c00292. eCollection 2024 Sep 23.
3
Recent Advances in CBP/EP300 Degraders.
Chimia (Aarau). 2025 Mar 26;79(3):137-145. doi: 10.2533/chimia.2025.137.
4
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Methods Mol Biol. 2021;2365:151-171. doi: 10.1007/978-1-0716-1665-9_8.
5
Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity.
Bioorg Med Chem Lett. 2024 Apr 1;102:129676. doi: 10.1016/j.bmcl.2024.129676. Epub 2024 Feb 24.
6
Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Bioorg Med Chem. 2023 Nov 15;95:117507. doi: 10.1016/j.bmc.2023.117507. Epub 2023 Oct 21.
7
Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Future Med Chem. 2022 Oct;14(19):1403-1416. doi: 10.4155/fmc-2022-0149. Epub 2022 Sep 1.
8
Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
J Biol Chem. 2022 Apr;298(4):101653. doi: 10.1016/j.jbc.2022.101653. Epub 2022 Jan 29.
9
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
ACS Chem Biol. 2023 Jan 20;18(1):25-33. doi: 10.1021/acschembio.2c00797. Epub 2023 Jan 6.
10
Recent advances in targeted protein degraders as potential therapeutic agents.
Mol Divers. 2024 Feb;28(1):309-333. doi: 10.1007/s11030-023-10606-w. Epub 2023 Feb 15.

引用本文的文献

1
CREB binding protein (CREBBP): Structure-based perspectives for the development of clinical inhibitors.
Transl Oncol. 2025 Aug 18;61:102507. doi: 10.1016/j.tranon.2025.102507.
3
Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.
J Med Chem. 2025 May 8;68(9):9638-9660. doi: 10.1021/acs.jmedchem.5c00395. Epub 2025 Apr 17.
5
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity.
JACS Au. 2024 Aug 8;4(9):3466-3474. doi: 10.1021/jacsau.4c00292. eCollection 2024 Sep 23.
6
Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300.
JACS Au. 2024 Jul 29;4(8):3094-3103. doi: 10.1021/jacsau.4c00442. eCollection 2024 Aug 26.
7
Discovery of an EP300 Inhibitor using Structure-based Virtual Screening and Bioactivity Evaluation.
Curr Pharm Des. 2024;30(25):1985-1994. doi: 10.2174/0113816128298051240529113313.
8
Paralogue-selective degradation of the lysine acetyltransferase EP300.
bioRxiv. 2024 May 5:2024.05.03.592353. doi: 10.1101/2024.05.03.592353.

本文引用的文献

1
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
J Med Chem. 2023 Jun 22;66(12):8178-8199. doi: 10.1021/acs.jmedchem.3c00492. Epub 2023 Jun 5.
2
Identification of ligand linkage vectors for the development of p300/CBP degraders.
RSC Med Chem. 2022 Apr 14;13(6):726-730. doi: 10.1039/d1md00070e. eCollection 2022 Jun 22.
3
PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.
5
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.
Cancer Discov. 2022 Mar 1;12(3):730-751. doi: 10.1158/2159-8290.CD-21-0385.
7
Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.
Genes (Basel). 2021 Jun 24;12(7):968. doi: 10.3390/genes12070968.
8
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras.
J Med Chem. 2021 Jun 24;64(12):8042-8052. doi: 10.1021/acs.jmedchem.1c00482. Epub 2021 Jun 9.
9
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Cell Chem Biol. 2021 Apr 15;28(4):503-514.e12. doi: 10.1016/j.chembiol.2020.12.004. Epub 2021 Jan 4.
10
Current development of CBP/p300 inhibitors in the last decade.
Eur J Med Chem. 2021 Jan 1;209:112861. doi: 10.1016/j.ejmech.2020.112861. Epub 2020 Oct 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验